China
Africa
Explore chapters and articles related to this topic
Betamethasone Valerate
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
A 52-year-old man with conjunctivitis developed marked periorbital edema and inflammation from prednisolone plus neomycin eyedrops. When betamethasone valerate 0.1% eye drops were ineffective, patch tests were performed yielding positive reactions to neomycin and betamethasone valerate (29). More case reports of allergic contact dermatitis from betamethasone valerate can be found in refs. 34,38,40,41, and 42. A Japanese author in 1994 reviewed the Japanese literature and found 11 reported cases of allergic contact dermatitis to betamethasone valerate in 10 articles published in the period 1986-1992 (21). Additional Japanese literature can be found in ref. 39.
Tazarotene
Published in John Y. M. Koo, Ethan C. Levin, Argentina Leon, Jashin J. Wu, Mark G. Lebwohl, Mild to Moderate Psoriasis, 2014
Monica Huynh, Chai Sue Lee, John Y. M. Koo
The combination of betamethasone valerate foam 0.12% (Luxiq®) and 0.1% tazarotene cream was shown to be effective in a case series of 10 psoriasis patients [24]. Two patients were clear of their psoriasis by week 4 and four were clear at week 8. Most importantly, no adverse events, including irritation, were reported. The authors report the use of the corticosteroid foam may protect against tazarotene-induced skin irritation, and the cosmetic appeal of a nongreasy corticosteroid foam improved patient compliance with the resultant high efficacy that was seen.
Topical Treatment of Atopic Dermatitis
Published in Donald Rudikoff, Steven R. Cohen, Noah Scheinfeld, Atopic Dermatitis and Eczematous Disorders, 2014
The effectiveness of pimecrolimus in the treatment of eczema is similar to that of lower-potency corticosteroids, such as hydrocortisone, dexamethasone, and betamethasone valerate 0.1%. Tacrolimus potency matches or exceeds that of midpotency products, hydrocortisone butyrate 0.1%, and betamethasone valerate 0.2% ointments (Rigopoulos et al. 2004, Ashcroft et al. 2005, Simpson and Noble 2005, Winiski et al. 2007). On the basis of large clinical trials, it is reasonable to use calcineurin inhibitors in patients with atopic dermatitis to prevent disease flares, reduce severity, lessen the need for topical corticosteroids, and sustain disease improvement.
Psoriasis patient preferences for topical drugs: a systematic review
Published in Journal of Dermatological Treatment, 2021
Mathias Tiedemann Svendsen, Steven R. Feldman, Sylvia Naiga Tiedemann, Anne Sofie Stochholm Sørensen, Cecilie Marie Ringgaard Rivas, Klaus Ejner Andersen
The efficacy of the topical drugs seemed to have an impact on patients’ preferences. One of the preferred topical drugs was betamethasone valerate, which was effective in reducing erythema, scaling, and itching, had a high bioavailability, and was effective in treating scalp psoriasis (21). These findings are in alignment with Stein et al. (32), who found that betamethasone valerate foam used twice daily for 12 weeks significantly reduced severity of mild-to-moderate plaque psoriasis. Mometasone emulsion was preferred over calcipotriol/betamethasone gel (28), as it was effective in treating mild-to-moderate scalp psoriasis and was associated with higher adherence rates. Calcipotriol betamethasone gel and foam were preferred by most patients over their most recently prescribed topical drugs, as it was effective in treating scalp psoriasis and improving adherence as well as patient quality of life (24). Patients preferring a new treatment over the old may be an impact of selection bias, as patients who like their old treatment are unlikely to enter a study testing a new medication.
Effects of a topical ointment on responses to treatments used for common genital diseases and on quality of life
Published in Cogent Medicine, 2020
Clarence de Belilovsky, Jean-Marc Bohbot
The results for the analysis of the clinical data are presented in Table 2. Steroids applied for maintenance therapy were: Clobetasol propionate 0.05% (n = 19), betamethasone dipropionate 0.05% (n = 5), diflucortone valerate 0.1% (n = 1) and betamethasone valerate 0.1% (n = 1). All patients kept the same steroid at the same posology during the study. They all applied the ointment once to twice daily. Except for dyspareunia, spontaneous pain and sclerosus/atrophy/synechia, the improvements of each criterion and of global scores were statistically significant (mGSS −80.61%, mGCS −59.2%). A total of 76.9% (20/26) attained mGSS75 and 23% (6/26) attained mGCS75; 84.6% (22/26) attained mGSS50 and 65.3% (17/26) attained mGCS50. The DLQI questionnaire was completed by 21 patients. The mean score decreased significantly, by 40.17% (Figure 1). A total of 73% of patients (19/26) attained an IGA ≥2. Tolerance was rated good by all patients. Representative photographs are shown (Figure 2, patients a and b).
Treatment of cutaneous lichen planus (Part 1): A review of topical therapies and phototherapy
Published in Cogent Medicine, 2019
Yasmeen Thandar, Rivesh Maharajh, Firoza Haffejee, Anisa Mosam
Class 1 (ultra-high potency) and Class II (high potency) topical corticosteroids are still considered the first line of treatment for CLP due to their anti-inflammatory properties that focus on localised lesions and reduce pruritus (Ramachandran, 2014). Six studies on topical corticosteroids were identified in the literature. Only one RCT was reported by Atzmony et al. (2016) which included betamethasone valerate 0.1% vs calcipotriol. In addition to that, four studies reported in the Atzmony et al. SR were non-randomised case-control trials (Atzmony et al., 2016). Two studies conducted before 1970 were reported by Cribier et al. (1998) but were excluded by Atzmony et al. (2016). A preceding study conducted in 1976 by Björnberg and Hellpen (1976) was only reported in a review by Manousaridis et al. (Hazra et al., 2013).